S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
ETR:MOR

MorphoSys Stock Forecast, Price & News

€34.76
+2.37 (+7.32%)
(As of 12/8/2021 12:00 AM ET)
Add
Compare
Today's Range
€34.23
€35.54
50-Day Range
€32.39
€42.69
52-Week Range
€32.41
€101.90
Volume
259,991 shs
Average Volume
153,687 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.


MorphoSys logo

About MorphoSys

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Headlines

MorphoSys Fell Too Far After M&A News, Analyst Says
June 3, 2021 |  finance.yahoo.com
MorphoSys acquires Constellation Pharma for $1.7B
June 2, 2021 |  bizjournals.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
615
Year Founded
N/A

Sales & Book Value

Annual Sales
$162.71 million
Cash Flow
€33.99 per share
Book Value
€17.49 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.19 billion
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.56 out of 5 stars

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












MorphoSys (ETR:MOR) Frequently Asked Questions

Is MorphoSys a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MorphoSys stock.
View analyst ratings for MorphoSys
or view top-rated stocks.

How has MorphoSys' stock been impacted by COVID-19 (Coronavirus)?

MorphoSys' stock was trading at €91.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MOR shares have decreased by 61.8% and is now trading at €34.76.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MOR?

8 brokerages have issued twelve-month price targets for MorphoSys' shares. Their forecasts range from €42.00 to €130.00. On average, they expect MorphoSys' share price to reach €79.00 in the next year. This suggests a possible upside of 127.3% from the stock's current price.
View analysts' price targets for MorphoSys
or view top-rated stocks among Wall Street analysts.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 56, Pay $2.06M)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 59, Pay $1.18M)
  • Dr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 49, Pay $1.19M)
  • Mr. Sung H. Lee, CFO & Member of Management Board (Age 51)
  • Mr. Klaus De Wall, Head of Accounting & Tax
  • Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban, Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn, Sr. VP & Head of Investor Relations
  • Dr. Armin Weidmann, Head of Compliance and Quality Assurance
  • Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 51)

What other stocks do shareholders of MorphoSys own?

What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €34.76.

How much money does MorphoSys make?

MorphoSys has a market capitalization of $1.19 billion and generates $162.71 million in revenue each year.

How many employees does MorphoSys have?

MorphoSys employs 615 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.de.

Where are MorphoSys' headquarters?

MorphoSys is headquartered at Semmelweisstr. 7, PLANEGG, 82152, Germany.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.